Related Experiment Video
Updated: Mar 30, 2026
05:18
Implantation of Left Ventricular Assist Device (LVAD) in Juvenile Landrace Swine: A LVAD Implantation Model of Pediatric Heart Failure
Published on: January 16, 2026
142
Left ventricular assist devices: current controversies and future directions
Erin M Schumer1, Matthew C Black1, Gretel Monreal1
1Department of Cardiovascular and Thoracic Surgery, University of Louisville, 201 Abraham Flexner Way, Suite 1200, Louisville, KY 40202, USA.
European Heart Journal
|November 7, 2015
Summary
Left ventricular assist devices (LVADs) improve survival and quality of life for advanced heart failure patients. This review covers LVAD history, outcomes, current challenges, and future directions in end-stage heart failure treatment.
Area of Science:
- Cardiology
- Medical Devices
- Heart Failure Management
Background:
- Advanced heart failure presents a significant and growing global health challenge.
- Left ventricular assist devices (LVADs) offer a therapeutic option for patients with end-stage heart failure.
- LVADs have demonstrated improvements in quality of life and long-term survival.
Purpose of the Study:
- To review the history and clinical outcomes of left ventricular assist devices (LVADs).
- To discuss current controversies and challenges associated with LVAD therapy.
- To explore future directions for LVADs in treating end-stage heart failure.
Main Methods:
- Literature review of historical data and clinical outcomes.
- Analysis of current issues and controversies in LVAD therapy.
- Discussion of future trends and research in the field.
Main Results:
- LVADs have evolved significantly, improving patient outcomes.
- Several controversies and challenges remain in LVAD implantation and management.
- The role of LVADs in heart failure treatment is expected to expand.
Conclusions:
- LVADs are a vital treatment for advanced heart failure, enhancing survival and quality of life.
- Addressing current challenges is crucial for optimizing LVAD therapy.
- Future research will likely focus on refining LVAD technology and expanding its application.
Related Concept Videos
01:29Cardiomyopathy V: Interprofessional Care
637
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
637
01:22Heart Failure VI: Adjunct Therapies
568
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
568
01:30Cardiomyopathy II: Dilated Cardiomyopathy
757
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
757
01:30Heart Failure V: Medical Management
532
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
532
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
708
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
708
01:29Heart Failure II: Pathophysiology
1.4K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.4K